Moderna expects to make 20 mln doses of COVID-19 vaccine candidate by 2020 end
Adds background on vaccine trials
Sept 18 (Reuters) - Moderna Inc MRNA.O said on Friday it expects to produce 20 million doses of its experimental coronavirus vaccine by the end of the year.
The company continues to expect to make 500 million to 1 billion doses of the vaccine in 2021, Moderna said in a filing with the U.S. securities regulator. (https://bit.ly/35PkSnc)
There are currently no COVID-19 vaccines approved by U.S. regulators, although a handful are in late-stage trials to prove they are safe and effective.
Moderna's COVID-19 vaccine is among the furthest in development and the company had enrolled 25,296 participants out of a planned 30,000 in its late-stage study as of Wednesday.
The Centers for Disease Control and Prevention anticipates that 35 million to 45 million doses of vaccines from the first two companies to receive authorization will be available in the United States by the end of this year.
Moderna has said it plans to seek emergency authorization for its vaccine's use in high-risk groups if it proves to be at least 70% effective.
(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.